Literature DB >> 14247510

FLUORINATED PYRIMIDINES. XXI. THE TUMOR-INHIBITORY ACTIVITY OF 5-TRIFLUOROMETHYL-2'-DEOXYURIDINE.

C HEIDELBERGER, S W ANDERSON.   

Abstract

Entities:  

Keywords:  BONE MARROW; CARCINOMA, EHRLICH TUMOR; EXPERIMENTAL LAB STUDY; GASTROINTESTINAL SYSTEM; LEUKEMIA L1210; LEUKOPENIA; LIGASES; MICE; PHARMACOLOGY; PYRIMIDINES; RATS; SARCOMA 180, CROCKER; TOXICOLOGIC REPORT; URACIL NUCLEOTIDES

Mesh：

Substances：

Year:  1964        PMID： 14247510

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  12 in total

1.  HEp-2 cell- and herpes simplex virus type 1- induced deoxythymidine kinases: inhibition by derivatives of 5-trifluoromethyl-2'-deoxyuridine.

Authors:  B L Wigdahl; J R Parkhurst
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

2.  Inhibition of mouse LM cell replication by trifluorothymidine: role of cytosolic deoxythymidine kinase.

Authors:  B L Wigdahl; J R Parkhurst
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191

3.  Experimental herpes simplex virus type 1 encephalitis: treatment with 5-trifluoromethyl-2'-deoxyuridine.

Authors:  D W Clough; J R Parkhurst
Journal:  Antimicrob Agents Chemother       Date:  1977-02       Impact factor: 5.191

4.  New active drugs for the treatment of advanced colorectal cancer.

Authors:  Alberto Zaniboni
Journal:  World J Gastrointest Surg       Date:  2015-12-27

5.  Antitumor activity of FTC-092, a masked 5-trifluoromethyl-2'-deoxyuridine derivative.

Authors:  S Takeda; J Yamashita; H Saito; J Uchida; H Satake; Y Yamada; N Unemi; Y Wataya; H Hayatsu
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

6.  Activity of trifluorothymidine against cytomegalovirus.

Authors:  J R Wingard; R K Stuart; R Saral; W H Burns
Journal:  Antimicrob Agents Chemother       Date:  1981-09       Impact factor: 5.191

7.  Potentiation of the antitumor activity of 5-trifluoromethyl-2'-deoxyuridine by the use of depot forms of the parent compound.

Authors:  S Takeda; K Wierzba; J Yamashita; H Matsumoto; H Satake; Y Yamada; N Unemi; Y Wataya; H Hayatsu
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 8.  Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies.

Authors:  Godefridus J Peters
Journal:  Ther Adv Med Oncol       Date:  2015-11       Impact factor: 8.168

9.  Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumors.

Authors:  Takayuki Yoshino; Takashi Kojima; Hideaki Bando; Tomoko Yamazaki; Yoichi Naito; Hirofumi Mukai; Nozomu Fuse; Koichi Goto; Yuko Ito; Toshihiko Doi; Atsushi Ohtsu
Journal:  Cancer Sci       Date:  2016-03-28       Impact factor: 6.716

10.  A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone.

Authors:  James M Cleary; Lee S Rosen; Kenichiro Yoshida; Drew Rasco; Geoffrey I Shapiro; Weijing Sun
Journal:  Invest New Drugs       Date:  2017-01-23       Impact factor: 3.850
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.